Drug intelligence / Profile preview

CKDB-103

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Small Molecules

Overview

CKDB-103 is an antiviral active pharmaceutical ingredient (API) currently in the research and development pipeline of CKD Bio, a subsidiary of the South Korean pharmaceutical company Chong Kun Dang. CKD Bio specializes in the development and production of APIs through advanced fermentation and chemical synthesis technologies. CKDB-103 is categorized within the company's API sector for the treatment of unspecified viral diseases. As an asset in the early stages of development, specific details regarding its molecular target, mechanism of action, and specific viral indications remain proprietary, with current efforts likely focused on process development and preclinical evaluation.

Beyond the preview

Go deeper on CKDB-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-103.

Explore the full profile